Table 4 Subgroup analysis of the association between CONUT and progression-free survival in patients with gynecological cancer

Total

4

2,279

Fixed

1.51 (1.25–1.84)

 < 0.001

0

0.682

Country

 China

3

1,942

Fixed

1.62 (1.28–2.05)

 < 0.001

0

0.803

 Others

1

337

-

1.30 (0.92–1.84)

0.138

-

-

Sample size

  < 300

1

206

-

1.67 (1.21–2.31)

0.002

-

-

  ≥ 300

3

2,073

Fixed

1.43 (1.12–1.82)

0.004

0

0.630

Cancer type

 Ovarian cancer

2

543

Fixed

1.49 (1.17–1.88)

0.001

7.3

0.299

 Cervical cancer

1

698

-

1.65 (1.13–2.42)

0.010

-

-

 Endometrial cancer

1

1,038

-

1.28 (0.61–2.67)

0.511

-

-

FIGO stage

 I-IV

3

1,581

Fixed

1.47 (1.17–1.84)

0.001

0

0.542

 I-II

1

698

-

1.65 (1.13–2.42)

0.010

-

-

Treatment

 Surgery

2

1,244

Fixed

1.60 (1.19–2.15)

0.002

0

0.516

 Surgery + CCRT/

Surgery + chemotherapy

2

1,035

Fixed

1.45 (1.12–1.87)

0.005

0

0.363

Study center

 Single center

3

1,581

Fixed

1.47 (1.17–1.84)

0.001

0

0.542

 Multicenter

1

698

-

1.65 (1.13–2.42)

0.010

-

-

Cut-off value

  = 3

2

904

Fixed

1.66 (1.30–2.13)

 < 0.001

0

0.964

  ≠ 3

2

1,375

Fixed

1.30 (0.95–1.77)

0.105

0

0.970

Age (median), years

  < 56

1

698

-

1.65 (1.13–2.42)

0.010

-

-

  ≥ 56

3

1,581

Fixed

1.47 (1.17–1.84)

0.001

0

0.542

NOS score

  < 8

3

1,241

Fixed

1.53 (1.25–1.87)

 < 0.001

0

0.525

  ≥ 8

1

1,038

-

1.28 (0.61–2.67)

0.511

-

-